Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Colonic Neoplasms × bexmarilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Sarcoma 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 202 Leucovorin 186 Oxaliplatin 181 Irinotecan 137 Bevacizumab 101 Capecitabine 83 Cetuximab 79 Folfox protocol 52 Chemotherapy, Adjuvant 33 Panitumumab 28 Colonoscopy 27 pembrolizumab 22 Drug Therapy 20 Blood Specimen Collection 20 Floxuridine 19 Nivolumab 18 Gemcitabine 18 Radiotherapy 17 IFL protocol 17 Magnetic Resonance Spectroscopy 16 Laparoscopy 16 Immunohistochemistry 16 Surveys and Questionnaires 15 Exercise 15 Early Intervention, Educational 15 Celecoxib 15 Neoadjuvant Therapy 14 Cyclophosphamide 14 Biopsy 14 trifluridine tipiracil drug combination 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05104905 2022-05-11

RENACOL

Faron Pharmaceuticals Ltd

Phase 1/2 Withdrawn

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡